메뉴 건너뛰기




Volumn 12, Issue 2, 2017, Pages

Correction: Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer (PLoS ONE (2017) 12:2 (e0171356) DOI: 10.1371/journal.pone.0171356);Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MESSENGER RNA; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE FRK; PROTEIN KINASE FYN; PROTEIN KINASE LCK; PROTEIN KINASE LYN; PROTEIN KINASE P60; PROTEIN KINASE YES; PROTEIN KINASE YES 1; SMALL INTERFERING RNA; TRASTUZUMAB; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; YES1 PROTEIN, HUMAN;

EID: 85011321109     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0174493     Document Type: Erratum
Times cited : (34)

References (39)
  • 1
    • 84964647508 scopus 로고    scopus 로고
    • European cancer mortality predictions for the year 2016 with focus on leukaemias
    • PMID : 26812903
    • Malvezzi M, Carioli G, Bertuccio P, Rosso T, Boffetta P, Levi F, et al. (2016) European cancer mortality predictions for the year 2016 with focus on leukaemias. Ann Oncol 27: 725-731. doi: 10.1093/annonc/mdw022 PMID: 26812903
    • (2016) Ann Oncol , vol.27 , pp. 725-731
    • Malvezzi, M.1    Carioli, G.2    Bertuccio, P.3    Rosso, T.4    Boffetta, P.5    Levi, F.6
  • 2
    • 84954400636 scopus 로고    scopus 로고
    • Cancer statistics, 2016
    • PMID : 26742998
    • Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66: 7-30. doi: 10.3322/caac.21332 PMID: 26742998
    • (2016) CA Cancer J Clin , vol.66 , pp. 7-30
    • Siegel, R.L.1    Miller, K.D.2    Jemal, A.3
  • 3
    • 84926454229 scopus 로고    scopus 로고
    • An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013
    • PMID : 25637502
    • Katanoda K, Hori M, Matsuda T, Shibata A, Nishino Y, Hattori M, et al. (2015) An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013. Jpn J Clin Oncol 45: 390-401. doi: 10.1093/jjco/hyv002 PMID: 25637502
    • (2015) Jpn J Clin Oncol , vol.45 , pp. 390-401
    • Katanoda, K.1    Hori, M.2    Matsuda, T.3    Shibata, A.4    Nishino, Y.5    Hattori, M.6
  • 4
    • 84980316341 scopus 로고    scopus 로고
    • Immunohistochemical surrogates for molecular classification of breast carcinoma: A 2015 update
    • PMID : 27472239
    • Tang P, Tse GM (2016) Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update. Arch Pathol Lab Med 140: 806-814. doi: 10.5858/arpa.2015-0133-RA PMID: 27472239
    • (2016) Arch Pathol Lab Med , vol.140 , pp. 806-814
    • Tang, P.1    Tse, G.M.2
  • 5
    • 34547676475 scopus 로고    scopus 로고
    • ERBB receptors: From oncogenes to targeted cancer therapies
    • PMID : 17671639
    • Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. (2007) ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117: 2051-2058. doi: 10.1172/JCI32278 PMID: 17671639
    • (2007) J Clin Invest , vol.117 , pp. 2051-2058
    • Zhang, H.1    Berezov, A.2    Wang, Q.3    Zhang, G.4    Drebin, J.5    Murali, R.6
  • 6
    • 51149092061 scopus 로고    scopus 로고
    • The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2
    • PMID : 18607391
    • Prat A, Baselga J (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 5: 531-542. doi: 10.1038/ncponc1179 PMID: 18607391
    • (2008) Nat Clin Pract Oncol , vol.5 , pp. 531-542
    • Prat, A.1    Baselga, J.2
  • 7
    • 1542329005 scopus 로고    scopus 로고
    • The ERBB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors
    • PMID : 14746530
    • Rowinsky EK (2004) The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 55: 433-457. doi: 10.1146/annurev.med.55.091902.104433 PMID: 14746530
    • (2004) Annu Rev Med , vol.55 , pp. 433-457
    • Rowinsky, E.K.1
  • 8
    • 84995814771 scopus 로고    scopus 로고
    • HER2 expression in gastric and oesophageal cancer: A meta-analytic review
    • PMID : 25830034
    • Nagaraja V, Eslick GD (2015) HER2 expression in gastric and oesophageal cancer: A meta-analytic review. J Gastrointest Oncol 6: 143-154 PMID: 25830034
    • (2015) J Gastrointest Oncol , vol.6 , pp. 143-154
    • Nagaraja, V.1    Eslick, G.D.2
  • 9
    • 0024337144 scopus 로고
    • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    • PMID : 2470152
    • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712. PMID: 2470152
    • (1989) Science , vol.244 , pp. 707-712
    • Slamon, D.J.1    Godolphin, W.2    Jones, L.A.3    Holt, J.A.4    Wong, S.G.5    Keith, D.E.6
  • 10
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • PMID : 11248153
    • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792. doi: 10.1056/NEJM200103153441101 PMID: 11248153
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3    Fuchs, H.4    Paton, V.5    Bajamonde, A.6
  • 11
    • 84869781977 scopus 로고    scopus 로고
    • Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
    • PMID : 22865781
    • Mohd Sharial MS, Crown J, Hennessy BT (2012) Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol 23: 3007-3016. doi: 10.1093/annonc/mds200 PMID: 22865781
    • (2012) Ann Oncol , vol.23 , pp. 3007-3016
    • Mohd Sharial, M.S.1    Crown, J.2    Hennessy, B.T.3
  • 12
    • 73349088416 scopus 로고    scopus 로고
    • Resistance to trastuzumab in breast cancer
    • PMID : 20008848
    • Pohlmann PR, Mayer IA, Mernaugh R (2009) Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 15: 7479-7491. doi: 10.1158/1078-0432.CCR-09-0636 PMID: 20008848
    • (2009) Clin Cancer Res , vol.15 , pp. 7479-7491
    • Pohlmann, P.R.1    Mayer, I.A.2    Mernaugh, R.3
  • 13
    • 78651387936 scopus 로고    scopus 로고
    • Resistance to HER2-targeted therapy: Mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment
    • PMID : 20972709
    • Hubalek M, Brunner C, Mattha K, Marth C (2010) Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Med Wochenschr 160: 506-512. doi: 10.1007/s10354-010-0838-6 PMID: 20972709
    • (2010) Wien Med Wochenschr , vol.160 , pp. 506-512
    • Hubalek, M.1    Brunner, C.2    Mattha, K.3    Marth, C.4
  • 14
    • 84886442748 scopus 로고    scopus 로고
    • Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2
    • PMID : 23948973
    • Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, et al. (2013) Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin Cancer Res 19: 5390-5401. doi: 10.1158/1078-0432. CCR-13-1038 PMID: 23948973
    • (2013) Clin Cancer Res , vol.19 , pp. 5390-5401
    • Rexer, B.N.1    Ghosh, R.2    Narasanna, A.3    Estrada, M.V.4    Chakrabarty, A.5    Song, Y.6
  • 15
    • 79959733118 scopus 로고    scopus 로고
    • Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
    • PMID : 21594665
    • Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, et al. (2011) Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 128: 447-456. doi: 10.1007/s10549-011-1572-5 PMID: 21594665
    • (2011) Breast Cancer Res Treat , vol.128 , pp. 447-456
    • Razis, E.1    Bobos, M.2    Kotoula, V.3    Eleftheraki, A.G.4    Kalofonos, H.P.5    Pavlakis, K.6
  • 16
    • 79953745096 scopus 로고    scopus 로고
    • Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
    • PMID : 21399647
    • Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, et al. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17: 461-469. doi: 10.1038/nm.2309 PMID: 21399647
    • (2011) Nat Med , vol.17 , pp. 461-469
    • Zhang, S.1    Huang, W.C.2    Li, P.3    Guo, H.4    Poh, S.B.5    Brady, S.W.6
  • 17
    • 79953738465 scopus 로고    scopus 로고
    • Trastuzumab resistance: All roads lead to SRC
    • PMID : 21475230
    • Muthuswamy SK (2011) Trastuzumab resistance: all roads lead to SRC. Nat Med 17: 416-418. doi: 10.1038/nm0411-416 PMID: 21475230
    • (2011) Nat Med , vol.17 , pp. 416-418
    • Muthuswamy, S.K.1
  • 18
    • 34247588567 scopus 로고    scopus 로고
    • Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
    • PMID : 17440164
    • Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: 628-638. doi: 10.1093/jnci/djk134 PMID: 17440164
    • (2007) J Natl Cancer Inst , vol.99 , pp. 628-638
    • Scaltriti, M.1    Rojo, F.2    Ocana, A.3    Anido, J.4    Guzman, M.5    Cortes, J.6
  • 19
    • 75149123144 scopus 로고    scopus 로고
    • Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
    • PMID : 19855434
    • Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, et al. (2010) Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 29: 325-334. doi: 10.1038/onc.2009.337 PMID: 19855434
    • (2010) Oncogene , vol.29 , pp. 325-334
    • Chandarlapaty, S.1    Scaltriti, M.2    Angelini, P.3    Ye, Q.4    Guzman, M.5    Hudis, C.A.6
  • 20
    • 5144226211 scopus 로고    scopus 로고
    • PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    • PMID : 15324695
    • Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127. doi: 10.1016/j.ccr.2004.06.022 PMID: 15324695
    • (2004) Cancer Cell , vol.6 , pp. 117-127
    • Nagata, Y.1    Lan, K.H.2    Zhou, X.3    Tan, M.4    Esteva, F.J.5    Sahin, A.A.6
  • 21
    • 12544250996 scopus 로고    scopus 로고
    • Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line
    • PMID : 15695389
    • Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, et al. (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65: 473-482. PMID: 15695389
    • (2005) Cancer Res , vol.65 , pp. 473-482
    • Nagy, P.1    Friedlander, E.2    Tanner, M.3    Kapanen, A.I.4    Carraway, K.L.5    Isola, J.6
  • 22
    • 84904065393 scopus 로고    scopus 로고
    • MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer
    • PMID : 24615544
    • Bai WD, Ye XM, Zhang MY, Zhu HY, Xi WJ, Huang X, et al. (2014) MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer 135: 1356-1368. doi: 10.1002/ijc.28782 PMID: 24615544
    • (2014) Int J Cancer , vol.135 , pp. 1356-1368
    • Bai, W.D.1    Ye, X.M.2    Zhang, M.Y.3    Zhu, H.Y.4    Xi, W.J.5    Huang, X.6
  • 23
    • 84958747623 scopus 로고    scopus 로고
    • Trastuzumab-resistant luminal b breast cancer cells show basal-like cell growth features through NF-kappaB-activation
    • PMID : 26871511
    • Kanzaki H, Mukhopadhya NK, Cui X, Ramanujan VK, Murali R (2016) Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-kappaB-Activation. Monoclon Antib Immunodiagn Immunother 35: 1-11. doi: 10.1089/mab.2015.0056 PMID: 26871511
    • (2016) Monoclon Antib Immunodiagn Immunother , vol.35 , pp. 1-11
    • Kanzaki, H.1    Mukhopadhya, N.K.2    Cui, X.3    Ramanujan, V.K.4    Murali, R.5
  • 24
    • 51549083821 scopus 로고    scopus 로고
    • Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
    • PMID : 18803986
    • Medina PJ, Goodin S (2008) Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30: 1426-1447. doi: 10.1016/j.clinthera.2008.08.008 PMID: 18803986
    • (2008) Clin Ther , vol.30 , pp. 1426-1447
    • Medina, P.J.1    Goodin, S.2
  • 25
    • 84971450036 scopus 로고    scopus 로고
    • Predictive factors of lapatinib and capecitabine activity in patients with her2-positive, trastuzumab-resistant metastatic breast cancer: Results from the Italian retrospective multicenter HERLAPAC study
    • PMID : 27224517
    • Gori S, Inno A, Rossi V, Turazza M, Fiorio E, Fabi A, et al. (2016) Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. PLoS One 11: e0156221. doi: 10.1371/journal.pone.0156221 PMID: 27224517
    • (2016) PLoS One , vol.11 , pp. e0156221
    • Gori, S.1    Inno, A.2    Rossi, V.3    Turazza, M.4    Fiorio, E.5    Fabi, A.6
  • 26
    • 84875215709 scopus 로고    scopus 로고
    • Investigation of the freely available easy-to-use software 'EZR' for medical statistics
    • PMID : 23208313
    • Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458. doi: 10.1038/bmt.2012.244 PMID: 23208313
    • (2013) Bone Marrow Transplant , vol.48 , pp. 452-458
    • Kanda, Y.1
  • 27
    • 79958292200 scopus 로고    scopus 로고
    • Promising molecular targeted therapies in breast cancer
    • PMID : 21713084
    • Munagala R, Aqil F, Gupta RC (2011) Promising molecular targeted therapies in breast cancer. Indian J Pharmacol 43: 236-245. doi: 10.4103/0253-7613.81497 PMID: 21713084
    • (2011) Indian J Pharmacol , vol.43 , pp. 236-245
    • Munagala, R.1    Aqil, F.2    Gupta, R.C.3
  • 28
    • 0030474489 scopus 로고    scopus 로고
    • C-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis
    • PMID : 9014858
    • Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A, et al. (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180: 383-388. doi: 10.1002/(SICI)1096-9896(199612)180:4383::AIDPATH6863.0.CO;2-N PMID: 9014858
    • (1996) J Pathol , vol.180 , pp. 383-388
    • Verbeek, B.S.1    Vroom, T.M.2    Adriaansen-Slot, S.S.3    Ottenhoff-Kalff, A.E.4    Geertzema, J.G.5    Hennipman, A.6
  • 29
  • 30
    • 84896530592 scopus 로고    scopus 로고
    • The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer
    • PMID : 24492292
    • Han S, Meng Y, Tong Q, Li G, Zhang X, Chen Y, et al. (2014) The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer. MAbs 6: 403-408. doi: 10.4161/mabs.27443 PMID: 24492292
    • (2014) MAbs , vol.6 , pp. 403-408
    • Han, S.1    Meng, Y.2    Tong, Q.3    Li, G.4    Zhang, X.5    Chen, Y.6
  • 31
    • 84902116278 scopus 로고    scopus 로고
    • Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models
    • PMID : 24887236
    • Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, et al. (2014) Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. Breast Cancer Res 16: R45. doi: 10.1186/bcr3650 PMID: 24887236
    • (2014) Breast Cancer Res , vol.16 , pp. R45
    • Formisano, L.1    Nappi, L.2    Rosa, R.3    Marciano, R.4    D'Amato, C.5    D'Amato, V.6
  • 32
    • 7944236785 scopus 로고    scopus 로고
    • Src family kinases, key regulators of signal transduction
    • PMID : 15489908
    • Parsons SJ, Parsons JT (2004) Src family kinases, key regulators of signal transduction. Oncogene 23: 7906-7909. doi: 10.1038/sj.onc.1208160 PMID: 15489908
    • (2004) Oncogene , vol.23 , pp. 7906-7909
    • Parsons, S.J.1    Parsons, J.T.2
  • 33
    • 84877868296 scopus 로고    scopus 로고
    • Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells
    • PMID : 23542356
    • Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu KL, et al. (2013) Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res 73: 3051-3061. doi: 10.1158/0008-5472.CAN-12-4136 PMID: 23542356
    • (2013) Cancer Res , vol.73 , pp. 3051-3061
    • Shien, K.1    Toyooka, S.2    Yamamoto, H.3    Soh, J.4    Jida, M.5    Thu, K.L.6
  • 34
    • 33745102555 scopus 로고    scopus 로고
    • Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias
    • PMID : 16775234
    • Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. (2006) Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-2541. doi: 10.1056/NEJMoa055229 PMID: 16775234
    • (2006) N Engl J Med , vol.354 , pp. 2531-2541
    • Talpaz, M.1    Shah, N.P.2    Kantarjian, H.3    Donato, N.4    Nicoll, J.5    Paquette, R.6
  • 35
    • 77957253177 scopus 로고    scopus 로고
    • Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells
    • PMID : 20811002
    • Seoane S, Montero JC, Ocana A, Pandiella A (2010) Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. J Natl Cancer Inst 102: 1432-1446. doi: 10.1093/jnci/djq315 PMID: 20811002
    • (2010) J Natl Cancer Inst , vol.102 , pp. 1432-1446
    • Seoane, S.1    Montero, J.C.2    Ocana, A.3    Pandiella, A.4
  • 36
    • 34249075147 scopus 로고    scopus 로고
    • MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    • PMID : 17463250
    • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. doi: 10.1126/science.1141478 PMID: 17463250
    • (2007) Science , vol.316 , pp. 1039-1043
    • Engelman, J.A.1    Zejnullahu, K.2    Mitsudomi, T.3    Song, Y.4    Hyland, C.5    Park, J.O.6
  • 37
    • 76749157917 scopus 로고    scopus 로고
    • Acquired resistance of nonsmall cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency
    • PMID : 20124471
    • McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J (2010) Acquired resistance of nonsmall cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 70: 1625-1634. doi: 10.1158/0008-5472.CAN-09-3620 PMID: 20124471
    • (2010) Cancer Res , vol.70 , pp. 1625-1634
    • McDermott, U.1    Pusapati, R.V.2    Christensen, J.G.3    Gray, N.S.4    Settleman, J.5
  • 38
    • 84982166645 scopus 로고    scopus 로고
    • An activating KIT mutation induces crizotinib resistance in ROS1-positive lung cancer
    • PMID : 27068398
    • Dziadziuszko R, Le AT, Wrona A, Jassem J, Camidge DR, Varella-Garcia M, et al. (2016) An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. J Thorac Oncol 11: 1273-1281. doi: 10.1016/j.jtho.2016.04.001 PMID: 27068398
    • (2016) J Thorac Oncol , vol.11 , pp. 1273-1281
    • Dziadziuszko, R.1    Le, A.T.2    Wrona, A.3    Jassem, J.4    Camidge, D.R.5    Varella-Garcia, M.6
  • 39
    • 69049115067 scopus 로고    scopus 로고
    • Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing
    • PMID : 19340424
    • Kute TE, Savage L, Stehle JR Jr., Kim-Shapiro JW, Blanks MJ, Wood J, et al. (2009) Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol Immunother 58: 1887-1896. doi: 10.1007/s00262-009-0700-0 PMID: 19340424
    • (2009) Cancer Immunol Immunother , vol.58 , pp. 1887-1896
    • Kute, T.E.1    Savage, L.2    Stehle, J.R.3    Kim-Shapiro, J.W.4    Blanks, M.J.5    Wood, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.